West Pharmaceutical Services reported Q4 FY2025 revenue of $805M and EPS of $2.04, beating expectations. Management guided FY2026 revenue of $3.215-$3.275B and EPS of $7.85-$8.20, with organic growth of 5-7% driven by HVP components. Key themes: strong GLP-1 demand, non-GLP-1 HVP recovery with capacity constraints, multi-year Annex I upgrade opportunity, and conservative assumptions on oral GLP-1 impact. Q4 revenue $805M (+3.3% organic), adjusted EPS $2.04 (+12% YoY), free cash flow $469M for FY2025.
West Pharmaceutical Services reported Q4 FY2025 revenue of $805M and EPS of $2.04, beating expectations. Management guided FY2026 revenue of $3.215-$3.275B and EPS of $7.85-$8.20, with organic growth of 5-7% driven by HVP components. Key themes: strong GLP-1 demand, non-GLP-1 HVP recovery with capacity constraints, multi-year Annex I upgrade opportunity, and conservative assumptions on oral GLP-1 impact. Q4 revenue $805M (+3.3% organic), adjusted EPS $2.04 (+12% YoY), free cash flow $469M for FY2025.
West Pharmaceutical Services reported Q4 FY2025 revenue of $805M and EPS of $2.04, beating expectations. Management guided FY2026 revenue of $3.215-$3.275B and EPS of $7.85-$8.20, with organic growth of 5-7% driven by HVP components. Key themes: strong GLP-1 demand, non-GLP-1…
Management emphasized strong momentum, robust demand, and a long-term growth outlook while framing 2026 guidance as conservative, especially regarding GLP-1 assumptions.
FY2026 guidance: revenue $3.215-$3.275B, EPS $7.85-$8.20, organic growth 5-7% with margins expanding >100bps.
HVP components grew 15% in Q4; non-GLP-1 HVP demand outstrips supply, driving capacity additions in Europe.
Non-GLP-1 HVP components to drive majority of 2026 growth. Management emphasized strong momentum, robust demand, and a long-term growth outlook while framing 2026 guidance as conservative, especially regarding GLP-1 assumptions.
West expects capital expenditures to step down again in 2026 to a range of $250 to $275 million as it moves back to spending 6% to 8% of sales. The company continues to ramp capacity in HVP components, particularly in Europe and the U.S., with investments focused more on labor and equipment than new facilities.
Management emphasized strong momentum, robust demand, and a long-term growth outlook while framing 2026 guidance as conservative, especially regarding GLP-1 assumptions.
“demand outstripped our supply . . . we're continuing to add capacity beyond what our expectations were”
“This represents less than 15% of the 6 billion components. We completed 65 projects in Q4 of 2025, with 325 Annex 1-related projects currently underway”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| Capex | FY2026 | $0.25B–$0.275B | $0.2625B | GUIDED |
| EPS | FY2026 | $7.85–$8.20 | $8.02 | GUIDED |
| EPS | FY2026 Q1 | $1.65–$1.70 | $1.67 | GUIDED |
| Revenue | FY2026 | $3.215B–$3.275B | $3.245B | GUIDED |
| Revenue | FY2026 Q1 | $770M–$790M | $780M | GUIDED |
| 제시 시점 | 지표 | 목표 기간 | 가이던스 | 실제 | 결과 |
|---|---|---|---|---|---|
| FY2026 Q1 | EPS | FY2026 Q2 | $2.05–$2.12 | $2.37 | Met / beat |
| FY2025 Q3 | EPS | FY2025 Q4 | $1.81–$1.86 | $2.04 | Met / beat |
| FY2025 Q3 | Revenue | FY2025 Q4 | $790–$800 | $805M | Met / beat |
Management cites Eli Lilly and Novo Nordisk's public commentary that oral GLP-1s are expanding the market rather than cannibalizing injectables, supporting continued demand for West's injectable components.
“I'd encourage you to listen to publicly available remarks from the two leading companies at producing GLP-1s and their expectation that orals will expand and not substitute injectables in the marketplace. Both companies have noted that”
… underway and more in the pipeline, we anticipate these projects will drive additional revenue growth in 2026 and beyond. Now, let me spend some time on oral GLP-1s and injectable formats. GLP-1s will continue to support our growth in 2026. As many of you are aware, oral GLP-1s have entered the market. And I want to share our view on their potential impact on the overall market. To provide context, I'd encourage you to listen to publicly available remarks from the two leading companies at producing GLP-1s and their expectation that orals will expand and not substitute injectables in the marketplace. Both companies have noted that eight of 10 patients using oral GLP-1s are new to the market. suggesting that orals will not cannibalize the injectables market and that several new injectables are about to launch. We expect growth from GLP-1 elastomers in 2026 and beyond for the following reasons. First and foremost, the adoption of GLP-1s is still in the early stages with penetration of the potential patient population in the low single digits by many estimates. market access is continuing to expand, driving volume. The available clinical evidence continues to show meaningful …
Demand for non-GLP-1 HVP components significantly outstripped supply in Q4, with West actively adding European capacity but demand growing faster, indicating tightness in biologics drug delivery components.